- < General Internal Medicine
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
By sjmartinez • March 27, 2025
Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, Wang Y, Ba Y, Li N, Zhang R, Zhang J, Chen Y, Chen J, Huang M, Fu Y, Liu M, Liu Z, Zhao J, Li W, Wei J, Li C, Xu N, Guo Z, Cao B, Liu L, Nie P, Wan L, Sheng L, Liu Z, He Y, Gu K, Wu G, Wang W, Zhang F, Qiu W, Guo J, Ying J, Pan H, Xu H, Yuan Y, Bai Y, Wang Z, Xu J, Zhao X, Liu H, Zhang X, Dai W, Xu H, Liu M, Xie L, Tang Y, Jin J, Qu X, Fang X, Huang M, Chen H, Zheng Z, Wang Y, Wang D, Li X, Yu G, Liu H, Zhou Y, Zhong D, Zeng S, Kang M, Wang M, Gao Y, Li W, Wang Z, Zhang M, Zhang J, Li Q, Sun S, Zang A, Lin L, Xie M, Zhuang Z, Zhang T, Yao Z, Lu D, Liu W, Hu M, Wang ZM, Li B, Xia M, Zhang J, Ying X, Pardoll DM, Ji J. Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025 Mar 26. doi: 10.1038/s41591-025-03666-y. Epub ahead of print. Erratum for: Nat Med. 2025 Jan 22. doi: 10.1038/s41591-024-03450-4. PMID: 40140623.
Related Posts
Moon R, Zeng E, Brach R, Lazarus ME. Co-occurrence of five chemotherapy induced nail findings. J Hosp Med. 2025 Jul 31. doi: 10.1002/jhm.70149. Epub ahead[...]
Kottakota H, Hotez E, Wilson RB. Survey of Child Neurologists Highlights a Missed Opportunity for Identifying and Treating Motor Impairments in Autism. Pediatr Neurol. 2025[...]
Zhu X, Shafi T, Norris KC, Simino J, Shrestha S, Mosley TH, Griswold ME, Lirette ST. Comparing methods for glomerular filtration rate estimation. J Clin[...]